SCHEMBL4917504

SCHEMBL4917504

CN(C)C1CCCC(N[C]=O)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1781231 0.77 IRAK4 (0.34)
SCHEMBL1766616 0.75 EPHX1 (0.31)
SCHEMBL115508 0.75
SCHEMBL21386086 0.74 ADH1B (0.32)
SCHEMBL18502882 0.74 ADH1B (0.32)
SCHEMBL4917512 0.72 ADH1A (0.58)
SCHEMBL18236726 0.71 MDM2 (0.35)
SCHEMBL4924932 0.71 DPP4 (0.33)
SCHEMBL20079170 0.71 MDM2 (0.35)
SCHEMBL20678853 0.71 DPP4 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080319019-A1 Therapeutic Agents ASTRAZENECA AB (SE) 2008-12-25 US disclosed
EP-1833802-A2 1,2-DIPHENYL-IMIDAZOLE DERIVATIVES AND THEIR USE AS CB1 RECEPTOR LIGANDS AstraZeneca AB (SE) 2007-09-19 EP disclosed
WO-2006067428-A2 1, 2-DIPHENYL-IMIDAZOLE DERIVATIVES AND THEIR USE AS CB1 RECEPTOR LIGANDS ASTRAZENECA AB (SE) 2006-06-29 WO disclosed